Genmab Clinical Trials
Sponsors / Genmab
The ClinicalTrials.gov registry records 48 trials led by Genmab. Across the portfolio, 12 are in recruitment, 8 are active non-recruiting, and 15 have reached completion. 13 trials have been terminated or withdrawn. The most common reasons cited for termination include business or strategic decisions, safety concerns. Across the portfolio, planned enrollment totals 6,969 participants. Data on this page mirrors the ClinicalTrials.gov registry as of the most recent refresh.
48
Total Trials
12
Recruiting
8
Other Active
15
Completed
13
Terminated / Withdrawn
6,969
Total Enrollment
Termination reasons: Other46% · Business31% · Safety23%
Recent Terminations
- NCT06685068 Stopped Mar 2026Advanced Solid Tumor"Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development."
- Nasopharyngeal Carcinoma"Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment"
- Endometrial Cancer"Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation"
- Acute Myeloid Leukemia (AML)"The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities."
- Malignant Solid Tumor"The sponsor has made the decision to terminate further development of GEN1078 based on emerging safety observations and overall benefit-risk assessment of 1078"
- Classical Hodgkin Lymphoma"Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio."
- Chronic Lymphocytic Leukemia"Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns."
- Colorectal Cancer"Sponsor decision"
- Head and Neck Cancer"The decision is based on company re-evaluation of indications to be pursued within SCCHN"
- Colorectal Cancer"Due to changes in portfolio review"
Active Trials (8 total)
- NCT05117242
- NCT06619236
- NCT07387068
- NCT07416123
- NCT06510491
- Cervical Cancer PHASE4NCT06952660
- NCT06635824
- Lymphoma PHASE2NCT07030699
- NCT07288177
- Breast Cancer, Breast Neoplasms PHASE1/PHASE2NCT05180474
- Breast Adenocarcinoma PHASE1/PHASE2NCT05579366
- NCT06573294
- Cutaneous Melanoma PHASE2NCT06984328
- Endometrial Cancer PHASE3NCT07166094
- Acute Myeloid Leukemia PHASE1NCT07384715
- NCT06811272
- Solid Tumors PHASE1/PHASE2NCT03917381
- NCT03485209
- CLL PHASE2NCT07108998
- NCT05578976